Lobbying Filing Details

Total Spending

$1,100,000

Activities

6

Lobbyists

14

Gov't Entities

78

Filing Information
Filing UUID:
e857a1fd-989b-4cd4-b0a6-589f7fe82f75
Type:
Q2 - 2nd Quarter - Report
Period:
2019 - 2nd Quarter (Apr 1 - June 30)
Date Posted:
July 18, 2019 at 5:49 PM
Income:
$0
Expenses:
$1,100,000
Expense Method:
Method A - Reporting amounts using LDA definitions only
Document URL:
View Submission
Quick Info
  • Document Type: text/html
  • Posted By: Beth Anne Cole
Registrant
ASSOCIATION FOR ACCESSIBLE MEDICINES

Association representing the interests of the generic pharmaceutical industry.

Washington, District of Columbia
Client
ASSOCIATION FOR ACCESSIBLE MEDICINES
District of Columbia, United States of America
Lobbying Activities (6)
Activity 1
Budget/Appropriations

FDA Funding.
Public Law 115-123: Bipartisan Budget Act of 2018.
Public Law 115-141: Consolidated Appropriations Act of 2018.

Lobbyists (9)
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • CHRISTIAN OMAR CRUZ
  • KARIN HESSLER
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more
Activity 2
Copyright/Patent/Trademark

Inter Partes Review (IPR) Process.
H.R.990/S.344: Hatch-Waxman Integrity Act of 2019.
Patent Settlements.
Patent Abuse.
Section 101 of the Patent Act.
New Chemical Entity Exclusivity (NCE).
REMEDY Act (Bill number not yet assigned).
S.440: Preserving Access to Cost Effective Drugs (PACED) Act.
H.R.2375: Preserve Access to Affordable Generics and Biosimilars Act.

Lobbyists (10)
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • CHRISTIAN OMAR CRUZ
  • KARIN HESSLER
  • JOSEPH STEWART
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more
Activity 3
Medicare/Medicaid

Medicare Part D Program and Generic Drugs.
Medicare Reimbursement for Biosimilars.
Medicaid Rebate Penalty.
Medicare Part D Low Income Subsidy (LIS) Program.
Medicare Part D Coverage Gap Discount Program.
H.R.448/S.99: Medicare Drug Price Negotiation Act.
H.R.275: Medicare Prescription Drug Price Negotiation Act of 2019.
S.62: Empowering Medicare Seniors to Negotiate Drug Prices Act of 2019.
H.R.1046/S.377: Medicare Negotiation and Competitive Licensing Act of 2019.
S.1895: Lower Health Care Costs Act.

Lobbyists (8)
  • CHRISTINE SIMMON
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • DANA MARIANI
  • JOSEPH STEWART
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more
Activity 4
Pharmacy

Implementation of Food and Drug Administration Reauthorization Act (FDARA).
Generic Drug User Fee Amendments (GDUFA).
Biosimilar User Fee Act (BsUFA).
Labeling of Generic Drugs.
Drug Compounding.
Drug Shortages.
Biosimilars Naming.
Biosimilars Insulin.
Pass Through Payments for Biosimilars.
Prescription Drug Costs.
American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.
Proposed Anti-Kickback Statute (AKS) Rebates.
FDA Citizen Petitions.
H.R.985: FAST Generics Act of 2019.
H.R.1506: FAIR Generics Act.
H.R.1503: Orange Book Transparency Act of 2019.
H.R.1520: Purple Book Continuity Act of 2019.
S.61: Safe and Affordable Drugs from Canada Act of 2019.
S.64: Preserve Access to Affordable Generics and Biosimilars Act.
S.1416: Affordable Prescriptions for Patients Act of 2019.
S.1224: Stop STALLING Act.
H.R.447/S.97: Affordable and Safe Prescription Drug Importation Act.
S.124: Freedom to Compete Act.
H.R.1499: Protecting Consumer Access to Generic Drugs Act of 2019.
H.R.938: Bringing Low-Cost Options and Competition while Keeping Incentives for New Generics (BLOCKING) Act of 2019.
H.R.465/S.102: Prescription Drug Price Relief Act of 2019.
H.R.1093/S. 378: Stop Price Gouging Act.
S.474: Stopping the Pharmaceutical Industry from Keeping Drugs Expensive (SPIKE) Act of 2019.
S.475: Reducing Existing Costs Associated with Pharmaceuticals for Seniors (RxCAP) Act of 2019.
S.476: Creating Transparency to Have Drug Rebates Unlocked (C-THRU) Act of 2019.
S.440: Preserving Access to Cost Effective Drugs (PACED) Act.
S.1895: Lower Health Care Costs Act.
H.R.965/S.340: CREATES Act of 2019.
Public Law 115-123: Bipartisan Budget Act of 2018.
Risk Evaluation and Mitigation Strategies (REMS).
Pharmaceutical Exclusivity.
Biologic Exclusivity.
H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act.
S.659: Biologic Patent Transparency Act.
Biologics Price Competition and Innovation Act (BPCIA).
Public Law 115-52: FDA Reauthorization Act of 2017.

Lobbyists (14)
  • CHRISTINE SIMMON
  • MICHAEL BRZICA
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • DAVID R. GAUGH
  • CRAIG BURTON
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • CHRISTIAN OMAR CRUZ
  • KARIN HESSLER
  • JONATHAN KIMBALL
  • DANA MARIANI
  • JOSEPH STEWART
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more
Activity 5
Taxation/Internal Revenue Code

Taxation Issues Related to Opioid Pharmaceuticals.
User Fee Programs.

Lobbyists (6)
  • MICHAEL BRZICA
  • CHRISTOPHER BOWLIN
  • DAVID R. GAUGH
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • CHRISTIAN OMAR CRUZ
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more
Activity 6
Trade (domestic/foreign)

General Trade Issues.
Trans-Pacific Partnership (TPP).
Transatlantic Trade and Investment Partnership (TTIP).
Biologic Exclusivity.
H.R.3379: Price Relief, Innovation, and Competition for Essential Drugs Act.
United States-Mexico-Canada Agreement (USMCA).
North American Free Trade Agreement (NAFTA).
U.S.-UK Trade Agreement.
U.S.-Japan Trade Discussions.
U.S.-India Trade Discussions.
U.S.-European Trade Negotiations.
China Tariffs.

Lobbyists (9)
  • MICHAEL BRZICA
  • CHESTER DAVIS JR
  • CHRISTOPHER BOWLIN
  • JEFFREY FRANCER
  • KRISTIN MURPHY
  • ERIK C KOMENDANT
  • CHRISTIAN OMAR CRUZ
  • JONATHAN KIMBALL
  • JOSEPH STEWART
Government Entities (13)
  • SENATE
  • HOUSE OF REPRESENTATIVES
  • Government Accountability Office (GAO)
  • Congressional Budget Office (CBO)
  • Office of Management & Budget (OMB)
  • ... and 8 more

Source: LDA.gov, data retrieved November 4, 2026. FilingExplorer is not affiliated with LDA.gov; the Senate Office of Public Records cannot vouch for data or analyses derived from these records after retrieval.